Biocon Q4 Results
Q4 a minor blip in Biocon's growth story, recovery expected in Q1FY21
Analysts estimate 38 per cent annual growth in earnings during FY20-22
 "Q4 a minor blip in Biocon's growth story, recovery expected in Q1FY21")
Updated On : 22 May 2020 | 1:37 AM IST
Will invest Rs 2k cr in small molecules segment in 3-4 yrs: Biocon CEO & MD
In a Q&A, Biocon CEO and MD Siddharth Mittal explains why he believes his company is on track to achieve the $1 billion revenue target from the segment by 2022
 "Will invest Rs 2k cr in small molecules segment in 3-4 yrs: Biocon CEO & MD")
Updated On : 15 May 2020 | 11:44 PM IST
Biocon's Q4 revenue hit by Covid-19 crisis, pre-tax profit declines 28%
The net profit for the period declined 42.2 per cent to Rs 123 crore on YoY basis, according to a BSE filing by the company
 "Biocon's Q4 revenue hit by Covid-19 crisis, pre-tax profit declines 28%")
Updated On : 15 May 2020 | 2:07 AM IST
Biocon posts growth of 64% in net profit at Rs 213.7 cr during Q4
Strong performance owing to growth in biologics, research services and small molecules business, says company
 "Biocon posts growth of 64% in net profit at Rs 213.7 cr during Q4")
Updated On : 25 Apr 2019 | 9:04 PM IST
